A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

607

Participants

Timeline

Start Date

December 6, 2017

Primary Completion Date

November 7, 2024

Study Completion Date

November 7, 2024

Conditions
Advanced Cancer
Interventions
BIOLOGICAL

BMS-986249

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

BIOLOGICAL

Ipilimumab

Specified dose on specified days

Trial Locations (45)

1121

Local Institution - 0038, Buenos Aires

2060

Local Institution - 0015, North Sydney

3084

Local Institution - 0047, Heidelberg

3199

Local Institution - 0025, Frankston

5000

Local Institution - 0014, Adelaide

10032

Local Institution - 0002, New York

10065

Local Institution - 0003, New York

19104

Local Institution - 0004, Philadelphia

20133

Local Institution - 0048, Milan

20176

Local Institution - 0012, Leesburg

20251

Local Institution - 0035, Hamburg

21287

Local Institution - 0024, Baltimore

23502

Local Institution - 0007, Norfolk

28027

Local Institution - 0022, Madrid

28040

Local Institution - 0023, Madrid

28041

Local Institution - 0050, Madrid

29010

Local Institution - 0043, Málaga

29605

Local Institution - 0008, Greenville

33176

Local Institution - 0017, Miami

45147

Local Institution - 0030, Essen

45219

Local Institution - 0029, Cincinnati

53100

Local Institution - 0049, Siena

69120

Local Institution - 0031, Heidelberg

75246

Local Institution - 0009, Dallas

75702

Local Institution - 0011, Tyler

77030

Local Institution - 0021, Houston

78240

Local Institution - 0016, San Antonio

80045

Local Institution - 0005, Aurora

80131

Local Institution - 0020, Napoli

80218

Local Institution - 0006, Denver

97401

Local Institution - 0013, Eugene

98684

Local Institution - 0018, Vancouver

200542

Local Institution - 0041, Craiova

8420383

Local Institution - 0036, Santiago

07601

Local Institution - 0001, Hackensack

78705-1165

Local Institution - 0010, Austin

C1430

Local Institution - 0052, CABA

C1426ANZ

Local Institution - 0037, Buenos Aires

T6G 1Z2

Local Institution - 0026, Edmonton

K1H 8L6

Local Institution - 0056, Ottawa

00029

Local Institution - 0039, Helsinki

02-781

Local Institution - 0040, Warsaw

022328

Local Institution - 0045, Bucharest

08916

Local Institution - 0042, Badalona

08035

Local Institution - 0044, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY